share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities

CRISPR Therapeutics | 4：持股變動聲明
SEC announcement ·  03/23 05:48
牛牛AI助理已提取核心訊息
CRISPR Therapeutics AG's Chief Executive Officer, Samarth Kulkarni, has engaged in a transaction involving the company's stock on March 20, 2024. The details of the transaction, including the number of shares involved and the transaction price, have not been disclosed in the announcement. The action reflects the CEO's dealings with the company's non-derivative securities. Investors are advised to note the involvement of a high-level executive in the company's stock transactions, which may be indicative of the company's internal confidence and future prospects.
CRISPR Therapeutics AG's Chief Executive Officer, Samarth Kulkarni, has engaged in a transaction involving the company's stock on March 20, 2024. The details of the transaction, including the number of shares involved and the transaction price, have not been disclosed in the announcement. The action reflects the CEO's dealings with the company's non-derivative securities. Investors are advised to note the involvement of a high-level executive in the company's stock transactions, which may be indicative of the company's internal confidence and future prospects.
CRISPR Therapeutics AG首席執行官薩瑪斯·庫爾卡尼已於2024年3月20日參與了一項涉及該公司股票的交易。該交易的細節，包括所涉及的股票數量和交易價格，尚未在公告中披露。該行動反映了首席執行官與公司非衍生證券的交易。建議投資者注意高級管理人員參與公司的股票交易，這可能表明公司的內部信心和未來前景。
CRISPR Therapeutics AG首席執行官薩瑪斯·庫爾卡尼已於2024年3月20日參與了一項涉及該公司股票的交易。該交易的細節，包括所涉及的股票數量和交易價格，尚未在公告中披露。該行動反映了首席執行官與公司非衍生證券的交易。建議投資者注意高級管理人員參與公司的股票交易，這可能表明公司的內部信心和未來前景。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。